Evaluation of SCF-engineered particle-based lactose blends in passive dry powder inhalers.
The objective of this study was to assess the performance of SCF-engineered budesonide and albuterol sulfate powder blends in passive dry powder inhalers (DPI) relative to micronized drug blends. A number of lactose grades for inhalation were screened and the appropriate carrier and drug-to-lactose blending ratio were selected based on drug content and emitted dose uniformity. Aerosol performance was characterized by Andersen cascade impaction. Blend formulations of SEDS (solution enhanced dispersion by supercritical fluids) budesonide and albuterol exhibited a significant drug content uniformity (7-9% RSD) improvement over micronized drug blends (16-20% RSD). Further, the SEDS formulations demonstrated higher emitted dose and reduced emitted dose variability (10-12% RSD) compared to micronized powders (21-25% RSD) in the Turbospin, albeit without significant enhancement of the fine particle fraction. In contrast, SEDS powders exhibited increased fine particle fractions over micronized blends in the Clickhaler; improvements were more pronounced with albuterol sulfate. The performance enhancements observed with the SEDS powders are attributed to their increased surface smoothness and reduced surface energy that are presumed to minimize irreversible drug-carrier particle interactions, thus resulting in more efficient drug detachment from the carrier particle surface during aerosolization. As demonstrated for budesonide and albuterol, SEDS may enhance performance of lactose blends and thus provide an attractive particle engineering option for the development of blend formulations for inhalation delivery.
Drug Delivery R&D, Nektar Therapeutics, 150 Industrial Road, San Carlos, CA 94070, USA.
Helena
H
Schiavone
Srinivas
S
Palakodaty
Andy
A
Clark
Peter
P
York
Stelios T
ST
Tzannis
D000280:Administration, Inhalation; D000420:Albuterol / Q000737:chemistry; D019819:Budesonide / Q000737:chemistry; D002626:Chemistry, Pharmaceutical / Q000379:methods; D025924:Chromatography, Supercritical Fluid / Q000379:methods*; D004337:Drug Carriers / Q000737:chemistry; D016503:Drug Delivery Systems / Q000379:methods; D004353:Drug Evaluation, Preclinical / Q000379:methods*; D005544:Forecasting; D007785:Lactose / Q000737:chemistry*; D036501:Metered Dose Inhalers / Q000639:trends; D008855:Microscopy, Electron, Scanning / Q000379:methods; D009330:Nebulizers and Vaporizers; D010316:Particle Size; D011208:Powders / Q000737:chemistry*; D006113:United Kingdom
D004337:Drug Carriers; D011208:Powders; D019819:Budesonide; D007785:Lactose; D000420:Albuterol